MedCrypt is Joined by Leading Health Tech Expert Axel Wirth as Chief Security Strategist

SAN DIEGO, Sept. 17, 2019 /PRNewswire/ — MedCrypt Inc., the proactive healthcare security provider, today announced Axel Wirth joined the company as chief security strategist (CSS). Wirth brings more than 30 years of experience in the medical device, healthcare IT and cybersecurity industries to MedCrypt, where he will help guide the company in critical security strategy decisions and support the adoption of critical security technology to the healthcare industry.

“I’ve always been impressed by Axel’s grasp of both the technical and clinical challenges of medical device security, and have closely followed his contributions to our community over the last three years,” said Mike Kijewski, MedCrypt CEO. “We couldn’t be happier to have him on our team, and look forward to facilitating his continued impact on our field for years to come.”

Prior to joining, Wirth was with leading cybersecurity provider Symantec, where he provided strategic vision and technical leadership, helping healthcare providers, industry partners and health technology professionals address their most challenging compliance, security and privacy challenges. He previously held roles at Siemens, Analogic, Mitra and Agfa as well. Wirth maintains certifications as an information systems security professional (CISSP), a healthcare information security and privacy practitioner (HCISPP) and a professional in health information systems and management (CPHIMS). He is an active participant in various healthcare organizations, such as Health Information Sharing and Analysis Center (H-ISAC), Healthcare Information and Management Systems Society (HIMSS) and the Association for the Advancement of Medical Instrumentation (AAMI), and serves on boards and committees across the industry.

“I’ve been an advocate for compliance, privacy, and security – and ultimately patient safety – in healthcare throughout my entire career,” said Axel Wirth, chief security strategist at MedCrypt. “I was pleased to find a team whose values align so closely with my own. MedCrypt’s mission involves protecting sensitive data and assuring patient safety by securing critical medical device and IT infrastructure. The healthcare industry is in dire need of this technology.”

Wirth received the ACCE-HIMSS Excellence in Clinical Engineering and IT Synergies Award and ACCE’s Clinical Engineering Advocacy Award, and in recognition of his contributions has been named a Fellow by two leading industry organizations, AAMI and HIMSS. His education includes a Bachelor of Science in Electrical Engineering from the University of Applied Sciences, Düsseldorf (Germany) and a Master of Science in Engineering Management from The Gordon Institute of Tufts University.

About MedCrypt, Inc.

MedCrypt is a San Diego-based company that provides proactive security for healthcare technology. MedCrypt’s solution encrypts data traveling to and from medical devices with just a few lines of code, ensuring devices are secure by design. MedCrypt announced a $5.3 million Series A funding round in May of 2019, bringing the total funds raised to $8.4 million with participation from Eniac Ventures, Section 32,  Y Combinator and more. The company is based in San Diego, California. For more, please visit www.medcrypt.com.

Contact: Brenda Manea
BAM Communications
brenda@bamcommunications.biz

View original content to download multimedia:http://www.prnewswire.com/news-releases/medcrypt-is-joined-by-leading-health-tech-expert-axel-wirth-as-chief-security-strategist-300919915.html

SOURCE MedCrypt

Staff

Recent Posts

Vor Bio Announces $55.6 Million Private Placement

Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33ALLO in the…

2 hours ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of…

2 hours ago

WEED Inc. President and CEO Releases Letter to Shareholders

TUCSON, Ariz., Dec. 27, 2024 (GLOBE NEWSWIRE) -- via IBN – WEED Inc. (OTCQB: BUDZ), (“WEED,”…

2 hours ago

Cara Therapeutics Announces Effective Date of 1-for-12 Reverse Stock Split

STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “Company”),…

2 hours ago

Park Ha Biological Technology Co., Ltd. Announces Pricing of $4.8 Million Initial Public Offering

Wuxi, China, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (the…

2 hours ago